AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

📰

Prostate cancer: the latest breakthroughs

Everything that changed in the last year, from three public sources: phase 3 trials that posted their results, papers in the leading medical and cancer journals, and US drug labels that were updated. Refreshed every week.

🤖

What changed

Written by AI from the evidence below, every point cited

AI reads the results, papers and label updates below and explains what changed and why it matters, citing each source. It is shared with everyone.

🏁

Phase 3 results posted

The large trials that decide new standard treatments · ClinicalTrials.gov
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN DeficiencyNCT04493853 · results posted 2026-09-10 · AstraZeneca · 1012 people · tests Capivasertib, Placebo, Abiraterone Acetate Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide AcetateNCT05605964 · results posted 2026-06-15 · Sumitomo Pharma America, Inc. · 387 people · tests Relugolix, Leuprolide Acetate Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate CancerNCT01368588 · results posted 2026-05-08 · Radiation Therapy Oncology Group · 2590 people · tests three-dimensional conformal radiotherapy, intensity modulated radiotherapy, Brachytherapy… Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical ProstatectomyNCT05678322 · results posted 2026-03-25 · NYU Langone Health · 26 people · tests 18F-Labeled Positron Emission Tomography (PET) Diagnostic Agent, PET MRI Imaging A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)NCT04497844 · results posted 2026-01-22 · Janssen Research & Development, LLC · 696 people · tests Niraparib+ Abiraterone acetate fixed dose combination (FDC), Abiraterone acetate (AA), Pr… Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal TreatmentNCT04647526 · results posted 2026-01-13 · POINT Biopharma, a wholly owned subsidiary of Eli… · 455 people · tests [Lu-177]-PNT2002, Abiraterone, Enzalutamide Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCNCT04446117 · results posted 2025-12-18 · Exelixis · 575 people · tests Cabozantinib, Atezolizumab, Abiraterone Acetate, Enzalutamide
📚

In the leading journals

NEJM, Lancet, Nature, JCO, Cancer Cell and more · PubMed
ctDNA clearance and outcomes for resectable lung cancer from NeoCOAST-2.Nature 2026 · PMID 42927884 Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 …Ann Oncol 2026 · PMID 42927858 From Diagnosis to Destruction: The Rise of Radioligand Therapeutics as Oncology's New Pillar.Ann Oncol 2026 · PMID 42927857 Pembrolizumab plus lenvatinib with belzutifan or quavonlimab as first-line therapy for advanced renal-cell carcinoma: randomized open-label…Ann Oncol 2026 · PMID 42927856 Final prespecified analysis of the phase 3 LITESPARK-011 study: belzutifan plus lenvatinib versus cabozantinib for advanced renal cell carc…Ann Oncol 2026 · PMID 42927855 Pembrolizumab with or without platinum-based chemotherapy as first-line treatment in advanced NSCLC expressing PD-L1 ≥50%: The PERSEE rando…Ann Oncol 2026 · PMID 42927854 A randomised phase III trial of adjuvant treatment intensification with mFOLFIRINOX versus mFOLFOX6 in high-risk stage III colon cancer: Re…Ann Oncol 2026 · PMID 42927853 Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer …Lancet Oncol 2026 · PMID 42927765 Neoadjuvant nivolumab with or without visugromab in muscle-invasive bladder cancer: the phase 2a GDFATHER-NEO trial.Nat Med 2026 · PMID 42926233 Relatlimab plus nivolumab versus nivolumab for advanced melanoma: 5-year survival and biomarker analyses of the phase 3 RELATIVITY-047 tria…Nat Med 2026 · PMID 42926136 Pembrolizumab Plus Chemotherapy for HR+/HER2- PD-L1‒Positive Advanced Breast Cancer: Final Analysis of the Phase 3 KEYNOTE-B49 Study.Ann Oncol 2026 · PMID 42926111 Atirmociclib and fulvestrant for patients with HR+/HER2- advanced/metastatic breast cancer who progressed on a prior cyclin-dependent kinas…Ann Oncol 2026 · PMID 42926110

Want these every week? Follow prostate cancer and get a note on your phone with the new trials and papers.

🔔 Follow prostate cancer
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy